(S)-4,5-Diaminopentanoic acid 2hcl | 130338-27-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-4,5-Diaminopentanoic acid 2hcl
• 英文别名: (4S)-4,5-diaminopentanoic acid;dihydrochloride
• CAS: 130338-27-1
• 化学式: C5H14Cl2N2O2
• 分子量: 205.08
• InChiKey: ZTPWEUZHVTXNBI-FHNDMYTFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8.29
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  92.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• TRANSITION METAL COMPLEXES FOR ENANTIOSELECTIVE CATALYSIS OF CARBON-CARBON, CARBON-HETEROATOM, AND CARBON-HYDROGEN BOND FORMING REACTIONS
  申请人：THE TEXAS A&M UNIVERSITY SYSTEM

  公开号：US20150165429A1

  公开（公告）日：2015-06-18

  In some embodiments, the present disclosure pertains to a compound, comprising a transition metal complex having the formula Φ-[M(x,y)-L 1 (w,v)-L 2 (t,u)-L 3 ] p+ An − m Z − p — m . In an embodiment of the present disclosure Φ may be A. In another embodiment Φ may be Δ. In some embodiments of the present disclosure, M is a transition metal. In a related embodiment, p is an integer corresponding to the oxidation state of M. In some embodiments of the present disclosure, each of x, y, w, v, t, and u independently comprise R. In other embodiments, each of x, y, w, v, t, and u independently comprise S. In an embodiment of the present disclosure, each of L 1 , L 2 , and L 3 independently is a ligand comprising a substituted diamine. In some embodiments, An″ comprises a lipophilic anion, where m is from 1 to 3, and where Z − comprises an optional second anion.

  在某些实施例中，本公开涉及一种化合物，包括具有公式Φ-[M（x，y）-L1（w，v）-L2（t，u）-L3]p+An−mZ−p—m的过渡金属配合物。在本公开的某种实施例中，Φ可以是A。在另一种实施例中，Φ可以是Δ。在本公开的某些实施例中，M是一种过渡金属。在相关实施例中，p是与M的氧化态相对应的整数。在本公开的某些实施例中，x，y，w，v，t和u中的每个都独立地包括R。在其他实施例中，x，y，w，v，t和u中的每个都独立地包括S。在本公开的某种实施例中，L1、L2和L3中的每个都独立地是包含取代二胺的配体。在某些实施例中，An″包括一个亲脂性阴离子，其中m从1到3，而Z−包括一个可选的第二个阴离子。
• Transition metal complexes for enantioselective catalysis of carbon-carbon, carbon-heteroatom, and carbon-hydrogen bond forming reactions
  申请人：Lewis Kyle G.

  公开号：US10189871B2

  公开（公告）日：2019-01-29

  In some embodiments, the present disclosure pertains to a compound, comprising a transition metal complex having the formula Φ-[M (x,y)-L1 (w,v)-L2 (t,u)-L3]p+An−mZ−p−m. In an embodiment of the present disclosure Φ may be Λ. In another embodiment Φ may be Δ. In some embodiments of the present disclosure, M is a transition metal. In a related embodiment, p is an integer corresponding to the oxidation state of M. In some embodiments of the present disclosure, each of x, y, w, v, t, and u independently comprise R. In other embodiments, each of x, y, w, v, t, and u independently comprise S. In an embodiment of the present disclosure, each of L1, L2, and L3 independently is a ligand comprising a substituted diamine. In some embodiments, An− comprises a lipophilic anion, where m is from 1 to 3, and where Z− comprises an optional second anion.

  在一些实施方案中，本公开涉及一种化合物，该化合物包含具有式 Φ-[M (x,y)-L1 (w,v)-L2 (t,u)-L3]p+An-mZ-p-m 的过渡金属配合物。在本公开的一个实施方案中，Φ 可以是Λ。在本公开的一些实施方案中，M 是过渡金属。在本公开的一些实施方案中，x、y、w、v、t和u中的每一个独立地包括R。在其它实施方案中，x、y、w、v、t和u中的每一个独立地包括S。在本公开的一个实施方案中，L1、L2和L3中的每一个独立地是包括取代二胺的配体。在一些实施方案中，An-包括亲脂阴离子，其中m为1至3，Z-包括任选的第二阴离子。
• Tridentate connexon and use thereof
  申请人：NEWBIO THERAPEUTICS, INC.

  公开号：US10960082B2

  公开（公告）日：2021-03-30

  Disclosed are a type of tridentate linkers and use thereof. The tridentate linkers can be used to prepare an antibody drug conjugates as represented by formula I, L-(T-A-D)n  I wherein, L is an antibody, antibody fragment or protein; T is a tridentate linker part; A is a cleavable linker group or a noncleavable linker part; D is a drug part; n is an integer of 0-8. The structure of the tridentate linker part is as represented by formula II, wherein, W is substituted aryl, heteroaryl, linear alkyl, cycloalkyl, heterocycloalkyl, or any combination thereof.

  本发明公开了一种三叉酯连接体及其用途。三叉酯连接体可用于制备由式 I 表示的抗体药物共轭物、 L-(T-A-D)n I 其中，L 是抗体、抗体片段或蛋白质；T 是三叉连接体部分；A 是可裂解连接体基团或不可裂解连接体部分；D 是药物部分；n 是 0-8 的整数。三叉连接体部分的结构如式 II 所示、 其中，W 是取代的芳基、杂芳基、直链烷基、环烷基、杂环烷基或它们的任意组合。
• TRIDENTATE CONNEXON AND USE THEREOF
  申请人：Newbio Therapeutics Inc.

  公开号：EP2949343B1

  公开（公告）日：2020-02-26
• TETRAMALEIMIDE LINKERS AND USE THEREOF
  申请人：NewBio Therapeutics, Inc.

  公开号：US20210128668A1

  公开（公告）日：2021-05-06

  The present invention is directed to tetramaleimide linkers and use thereof, more specifically to the compounds represented by formula I and their use in the preparation of antibody-drug conjugates (ADCs). The ADCs obtained from the tetramaleimide linkers have high homogeneity and stability, and could be used effectively for the treatment of various diseases including tumors. The definition of the groups in formula I is the same as that in the description.